Cargando…
Anlotinib Exerts Inhibitory Effects against Cisplatin-Resistant Ovarian Cancer In Vitro and In Vivo
Background: Anlotinib is a highly potent multi-target tyrosine kinase inhibitor. Accumulating evidence suggests that anlotinib exhibits effective anti-tumor activity against various cancer subtypes. However, the effects of anlotinib against cisplatin-resistant (CIS) ovarian cancer (OC) are yet to be...
Autores principales: | Ji, Yurou, Li, Xinyu, Qi, Yue, Zhao, Jianguo, Zhang, Wenwen, Qu, Pengpeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785832/ https://www.ncbi.nlm.nih.gov/pubmed/36558006 http://dx.doi.org/10.3390/molecules27248873 |
Ejemplares similares
-
The inhibitory effect of 6-gingerol and cisplatin on ovarian cancer and antitumor activity: In silico, in vitro, and in vivo
por: Salari, Zohreh, et al.
Publicado: (2023) -
Anlotinib exerts anti‐cancer efficiency on lung cancer stem cells in vitro and in vivo through reducing NF‐κB activity
por: Li, Zhuohong, et al.
Publicado: (2021) -
Identification of a novel pyridine derivative with inhibitory activity against ovarian cancer progression in vivo and in vitro
por: Si, Lulu, et al.
Publicado: (2022) -
Anlotinib as Exploratory Therapy for Platinum-Resistant Ovarian Cancer: A Retrospective Study on Efficacy and Safety
por: Ni, Jing, et al.
Publicado: (2020) -
Clarithromycin synergizes with cisplatin to inhibit ovarian cancer growth in vitro and in vivo
por: Zhou, Bo, et al.
Publicado: (2019)